• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cloning, expression and immunogenicity of the translation initiation factor 3 homologue of Brucella abortus.

作者信息

González Marcela, Andrews Edilia, Folch Hugo, Sáez Darwin, Cabrera Alex, Salgado Paulina, Oñate Angel

机构信息

Department of Microbiology, Faculty of Biological Sciences, Molecular Immunology Laboratory, Universidad de Concepción, Concepción, Chile.

出版信息

Immunobiology. 2009;214(2):113-20. doi: 10.1016/j.imbio.2008.07.004. Epub 2008 Aug 26.

DOI:10.1016/j.imbio.2008.07.004
PMID:19167989
Abstract

The infC gene of Brucella abortus encoding the translation initiation factor 3 (IF3) was cloned, sequenced and expressed in Escherichia coli. The amino acid sequence analysis predicted a product with 74-80% identity with the IF3 proteins from Mesorhizobium loti, Sinorhizobium meliloti, Aurantimona sp. and Mesorhizobium sp. This protein also show 54% amino acid sequence identity with the E. coli IF3, sharing most of the residues which were described as responsible for the biological activity of this protein. Since we have previously reported the immunoprotective capacity of this Brucella protein, we stimulated lymphoid cells from animals immunized with purified recombinant Brucella IF3 protein "in vitro" with this antigen. The lymphocytes were able to mount a strong proliferative response with concomitant production of gamma interferon, but without the secretion of either IL-4 or antibodies. Thus, immunization with the Brucella recombinant IF3 protein promotes a TH-1 polarized response, allowing us to propose it as a promising candidate antigen for the development of subunit vaccines against Brucella.

摘要

相似文献

1
Cloning, expression and immunogenicity of the translation initiation factor 3 homologue of Brucella abortus.
Immunobiology. 2009;214(2):113-20. doi: 10.1016/j.imbio.2008.07.004. Epub 2008 Aug 26.
2
Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice.用表达流产布鲁氏菌翻译起始因子3的重组塞姆利基森林病毒颗粒进行疫苗接种可诱导BALB/c小鼠产生保护性免疫。
Immunobiology. 2009;214(6):467-74. doi: 10.1016/j.imbio.2008.11.016. Epub 2009 Jan 17.
3
Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.以含CpG寡脱氧核苷酸作为佐剂,用细菌铁蛋白或P39重组蛋白对BALB/c小鼠进行免疫接种,以保护其免受流产布鲁氏菌544的攻击。
Infect Immun. 2001 Aug;69(8):4816-22. doi: 10.1128/IAI.69.8.4816-4822.2001.
4
Recombinant Brucella abortus proteins that induce proliferation and gamma-interferon secretion by CD4+ T cells from Brucella-vaccinated mice and delayed-type hypersensitivity in sensitized guinea pigs.重组流产布鲁氏菌蛋白,可诱导接种布鲁氏菌的小鼠的CD4 + T细胞增殖和γ-干扰素分泌,并在致敏豚鼠中引发迟发型超敏反应。
Cell Immunol. 1996 Sep 15;172(2):262-8. doi: 10.1006/cimm.1996.0241.
5
Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.用重组布鲁氏菌属外膜蛋白Omp16或Omp19与佐剂一起免疫可诱导特异性CD4 +和CD8 + T细胞,以及对流产布鲁氏菌感染的全身和口腔保护。
Infect Immun. 2009 Jan;77(1):436-45. doi: 10.1128/IAI.01151-08. Epub 2008 Nov 3.
6
Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.用一种新型重组分子伴侣对小鼠进行免疫可使其免受羊布鲁氏菌感染。
Vaccine. 2014 Nov 20;32(49):6659-66. doi: 10.1016/j.vaccine.2014.09.013. Epub 2014 Sep 19.
7
Protection of BALB/C mice against Brucella abortus 544 challenge by vaccination with combination of recombinant human serum albumin-l7/l12 (Brucella abortus ribosomal protein) and lipopolysaccharide.通过用重组人血清白蛋白-l7/l12(流产布鲁氏菌核糖体蛋白)和脂多糖联合疫苗接种来保护BALB/C小鼠免受流产布鲁氏菌544的攻击。
Roum Arch Microbiol Immunol. 2010 Jan-Mar;69(1):5-12.
8
Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2.通过表达与白细胞介素-2融合的铜锌超氧化物歧化酶抗原评估流产布鲁氏菌DNA疫苗。
Immunobiology. 2006;211(1-2):65-74. doi: 10.1016/j.imbio.2005.09.004. Epub 2005 Dec 27.
9
Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice.用布鲁氏菌重组DnaK和SurA蛋白进行疫苗接种可诱导BALB/c小鼠对流产布鲁氏菌感染产生保护作用。
Vaccine. 2007 Sep 17;25(37-38):6721-9. doi: 10.1016/j.vaccine.2007.07.002. Epub 2007 Jul 23.
10
Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model.人血清白蛋白- L7/L12(流产布鲁氏菌核糖体蛋白)在动物模型中的免疫原性。
Iran J Immunol. 2009 Mar;6(1):12-21.

引用本文的文献

1
Immunization with S19Δ Conferred Protection in Water Buffaloes against Virulent Challenge with Strain S544.用S19Δ免疫水牛可使其免受S544毒株的强毒攻击。
Vaccines (Basel). 2021 Dec 2;9(12):1423. doi: 10.3390/vaccines9121423.
2
Diagnostic potential of Rev1 native Omp28 precursor in human brucellosis.Rev1天然Omp28前体在人类布鲁氏菌病中的诊断潜力
Cent Eur J Immunol. 2018;43(1):81-89. doi: 10.5114/ceji.2018.74877. Epub 2018 Mar 30.
3
Immunogenicity of a Multi-Epitope DNA Vaccine Encoding Epitopes from Cu-Zn Superoxide Dismutase and Open Reading Frames of in Mice.
编码来自铜锌超氧化物歧化酶的表位和小鼠中开放阅读框的多表位DNA疫苗的免疫原性。
Front Immunol. 2017 Feb 9;8:125. doi: 10.3389/fimmu.2017.00125. eCollection 2017.
4
Cloning, expression, and characterization of TonB2 from Actinobacillus pleuropneumoniae and potential use as an antigenic vaccine candidate and diagnostic marker.胸膜肺炎放线杆菌TonB2的克隆、表达与特性分析及其作为抗原性疫苗候选物和诊断标志物的潜在用途。
Can J Vet Res. 2011 Jul;75(3):183-90.
5
Enzymatic and biological characteristics of enolase in Brucella abortus A19.布鲁氏菌 A19 烯醇酶的酶学及生物学特性
Mol Biol Rep. 2012 Mar;39(3):2705-11. doi: 10.1007/s11033-011-1025-6. Epub 2011 Jun 15.
6
Brucellosis: the case for live, attenuated vaccines.布鲁氏菌病:减毒活疫苗的情况
Vaccine. 2009 Nov 5;27 Suppl 4(Suppl 4):D40-3. doi: 10.1016/j.vaccine.2009.08.058.